Evidence map›Paper›PMID 41198749›Full record

ArticleScientific reports2025

TREM2 expressing macrophages are not associated with prognostic markers or metabolic syndrome in early stage ER positive breast cancer.

Elysa W Pierro, Guadalupe A Garcia, Violeta M Sanchez, Paula I Gonzalez-Ericsson, Barbara Fingleton, Alyssa H Hasty, Brent N Rexer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elysa W PierroDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-0011-2112
Guadalupe A GarciaDepartment of Medicine, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0009-0002-3073-7495
Violeta M SanchezDepartment of Medicine, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-6639-9024
Paula I Gonzalez-EricssonDepartment of Medicine, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-6292-6963
Barbara FingletonVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-1132-0782
Alyssa H HastyDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-7302-8045
Brent N RexerDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, 1161 21st Ave S, Nashville, TN, 37232, USA. brent.rexer@vumc.org.ORCID http://orcid.org/0000-0002-0341-7392

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7M
BLRD VA I01 BX002195BLRD VA IK6 BX005649Mark Foundation For Cancer Research Endeavor AwardNCI NIH HHS P30 CA068485NCI NIH HHS P50 CA098131NCI NIH HHS P50CA098131
6 · The paper itself

Abstract

Triggering receptor expressed on myeloid cells 2 (TREM2) has been shown to confer immunosuppressive effects when expressed on tumor associated macrophages and thus has become a prominent focus of cancer research in recent years. The primary aims of this study were to explore the distribution of TREM2-expressing macrophages in early-stage ER+ breast cancer, specifically asking if there is a correlation with tumor aggressiveness and/or metabolic syndrome. To address these aims, we performed immunofluorescent staining for TREM2, CD68, and DAPI in 95 early-stage breast cancer samples from patients who underwent surgery at Vanderbilt University Medical Center. We assessed associations between TREM2

Indexed as

Biomarkers, TumorBreast NeoplasmsMacrophagesMembrane GlycoproteinsMetabolic SyndromeReceptors, EstrogenReceptors, ImmunologicAdultAgedFemaleHumansMiddle AgedNeoplasm StagingPrognosisBiomarkers, TumorMembrane GlycoproteinsReceptors, EstrogenReceptors, ImmunologicTREM2 protein, human

Identifiers

PMID41198749
PMCPMC12592553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.